Bristol-Myers Squibb Co - Company Profile
Powered by
All the data and insights you need on Bristol-Myers Squibb Co in one report.
- Save hours of research time and resources with
our up-to-date Bristol-Myers Squibb Co Strategy Report
- Understand Bristol-Myers Squibb Co position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreBristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.
Bristol-Myers Squibb Co premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Cardiovascular Drugs | Abecma |
Diabetes Alliance Products | Abraxane |
Virology Drugs | Azactam |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In May, the company entered into a partnership with the schizophrenia community to introduce Live Your PosSCZible, a national campaign. |
2024 | Regulatory Approval | In May, the company received approval from the European Medicines Agency for its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer. |
2024 | Contracts/Agreements | In April, the company signed a research collaboration with Scenic Biotech to enhance the development of Bristol Myers Squibb’s drug. |
Competitor Comparison
Key Parameters | Bristol-Myers Squibb Co | Johnson & Johnson | Merck & Co Inc | Sanofi | Novartis AG |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | France | Switzerland |
City | Princeton | New Brunswick | Rahway | Paris | Basel |
State/Province | New Jersey | New Jersey | New Jersey | Ile-de-France | - |
No. of Employees | 34,100 | 131,900 | 72,000 | 87,994 | 76,057 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Christopher S. Boerner Ph.D. | Chairman; Chief Executive Officer | Executive Board | 2024 | - |
David V. Elkins | Chief Financial Officer; Executive Vice President | Senior Management | 2019 | 55 |
Paul von Autenried | Executive Vice President; Chief Information Officer | Senior Management | 2019 | 60 |
Samit Hirawat, M.D. | Executive Vice President; Head - Development; Chief Medical Officer - Global Drug Development | Senior Management | 2019 | 55 |
Robert Plenge, MD, Ph.D | Chief Research Officer; Executive Vice President; Head - Research | Senior Management | 2023 | 53 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer